Susquehanna International Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-153,000
Closed -$48.4M 13734
2023
Q4
$48.4M Buy
153,000
+56,400
+58% +$11M 0.01% 1061
2023
Q3
$16.3M Sell
96,600
-6,200
-6% -$1.17M ﹤0.01% 1966
2023
Q2
$22.3M Sell
102,800
-9,000
-8% -$1.93M ﹤0.01% 1625
2023
Q1
$20.3M Buy
111,800
+72,300
+183% +$13.8M ﹤0.01% 1690
2022
Q4
$7.76M Sell
39,500
-15,800
-29% -$3.39M ﹤0.01% 2615
2022
Q3
$12.4M Sell
55,300
-5,100
-8% -$1.03M ﹤0.01% 1901
2022
Q2
$7.64M Buy
60,400
+22,000
+57% +$2.53M ﹤0.01% 2576
2022
Q1
$4.87M Buy
38,400
+33,600
+700% +$3.78M ﹤0.01% 3682
2021
Q4
$629K Sell
4,800
-22,600
-82% -$2.92M ﹤0.01% 8543
2021
Q3
$3.35M Sell
27,400
-28,500
-51% -$3.29M ﹤0.01% 4724
2021
Q2
$6.37M Sell
55,900
-24,200
-30% -$2.83M ﹤0.01% 3589
2021
Q1
$9.63M Buy
80,100
+36,600
+84% +$4.15M ﹤0.01% 2822
2020
Q4
$4.42M Sell
43,500
-11,400
-21% -$1.06M ﹤0.01% 3624
2020
Q3
$4.25M Sell
54,900
-21,000
-28% -$1.79M ﹤0.01% 3281
2020
Q2
$8.46M Buy
75,900
+34,900
+85% +$3.03M ﹤0.01% 2344
2020
Q1
$2.95M Buy
+41,000
New +$3.51M ﹤0.01% 3311

Other funds holding KRTX

Susquehanna International Group's KRTX Position: Q1 2024 in Review

Susquehanna International Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 38,118 shares — an estimated $12.1M sold.

Susquehanna International Group first reported a position in KRTX in Q1 2020 and held it in 16 quarters. The position peaked at $22.9M in Q2 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Susquehanna International Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 38,118 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.1M.
  • Susquehanna International Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2020 and held it in 16 quarters.
  • Susquehanna International Group's Karuna Therapeutics, Inc. Common Stock position peaked at $22.9M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.